161 related articles for article (PubMed ID: 26103538)
1. Inflammatory markers and cardiometabolic diseases.
Esser N; Paquot N; Scheen AJ
Acta Clin Belg; 2015 Jun; 70(3):193-9. PubMed ID: 26103538
[TBL] [Abstract][Full Text] [Related]
2. Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease.
Esser N; Paquot N; Scheen AJ
Expert Opin Investig Drugs; 2015 Mar; 24(3):283-307. PubMed ID: 25345753
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in the relationship between obesity, inflammation, and insulin resistance.
Bastard JP; Maachi M; Lagathu C; Kim MJ; Caron M; Vidal H; Capeau J; Feve B
Eur Cytokine Netw; 2006 Mar; 17(1):4-12. PubMed ID: 16613757
[TBL] [Abstract][Full Text] [Related]
4. The role of inflammatory cytokines in diabetes and its complications.
King GL
J Periodontol; 2008 Aug; 79(8 Suppl):1527-34. PubMed ID: 18673007
[TBL] [Abstract][Full Text] [Related]
5. Low-grade systemic inflammation and the risk of type 2 diabetes in obese children and adolescents.
Syrenicz A; Garanty-Bogacka B; Syrenicz M; Gebala A; Walczak M
Neuro Endocrinol Lett; 2006 Aug; 27(4):453-8. PubMed ID: 16892000
[TBL] [Abstract][Full Text] [Related]
6. C-reactive protein, its role in inflammation, Type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones.
Nesto R
Diabet Med; 2004 Aug; 21(8):810-7. PubMed ID: 15270782
[TBL] [Abstract][Full Text] [Related]
7. Adipose tissue inflammation in obesity and metabolic syndrome.
Nishimura S; Manabe I; Nagai R
Discov Med; 2009 Aug; 8(41):55-60. PubMed ID: 19788868
[TBL] [Abstract][Full Text] [Related]
8. Metabolic and inflammatory profiles of biomarkers in obesity, metabolic syndrome, and diabetes in a Mediterranean population. DARIOS Inflammatory study.
Fernández-Bergés D; Consuegra-Sánchez L; Peñafiel J; Cabrera de León A; Vila J; Félix-Redondo FJ; Segura-Fragoso A; Lapetra J; Guembe MJ; Vega T; Fitó M; Elosua R; Díaz O; Marrugat J
Rev Esp Cardiol (Engl Ed); 2014 Aug; 67(8):624-31. PubMed ID: 25037541
[TBL] [Abstract][Full Text] [Related]
9. Antidiabetic agents: Potential anti-inflammatory activity beyond glucose control.
Scheen AJ; Esser N; Paquot N
Diabetes Metab; 2015 Jun; 41(3):183-94. PubMed ID: 25794703
[TBL] [Abstract][Full Text] [Related]
10. Metabolic obesity, adipocytokines, and inflammatory markers in Asian Indians--CURES-124.
Indulekha K; Surendar J; Anjana RM; Geetha L; Gokulakrishnan K; Pradeepa R; Mohan V
Diabetes Technol Ther; 2015 Feb; 17(2):134-41. PubMed ID: 25478993
[TBL] [Abstract][Full Text] [Related]
11. Abdominal adiposity and cardiometabolic risk: do we have all the answers?
Haffner SM
Am J Med; 2007 Sep; 120(9 Suppl 1):S10-6; discussion S16-7. PubMed ID: 17720354
[TBL] [Abstract][Full Text] [Related]
12. Hepatic insulin resistance, metabolic syndrome and cardiovascular disease.
Meshkani R; Adeli K
Clin Biochem; 2009 Sep; 42(13-14):1331-46. PubMed ID: 19501581
[TBL] [Abstract][Full Text] [Related]
13. Visceral adipose tissue indicates the severity of cardiometabolic risk in patients with and without type 2 diabetes: results from the INSPIRE ME IAA study.
Smith JD; Borel AL; Nazare JA; Haffner SM; Balkau B; Ross R; Massien C; Alméras N; Després JP
J Clin Endocrinol Metab; 2012 May; 97(5):1517-25. PubMed ID: 22337910
[TBL] [Abstract][Full Text] [Related]
14. Effects of grape seed extract in Type 2 diabetic subjects at high cardiovascular risk: a double blind randomized placebo controlled trial examining metabolic markers, vascular tone, inflammation, oxidative stress and insulin sensitivity.
Kar P; Laight D; Rooprai HK; Shaw KM; Cummings M
Diabet Med; 2009 May; 26(5):526-31. PubMed ID: 19646193
[TBL] [Abstract][Full Text] [Related]
15. The importance of treating multiple cardiometabolic risk factors in patients with Type 2 diabetes.
Mikhailidis DP; Press M
Expert Opin Pharmacother; 2007 Dec; 8(17):3009-20. PubMed ID: 18001259
[TBL] [Abstract][Full Text] [Related]
16. Proinflammatory markers, insulin sensitivity, and cardiometabolic risk factors in treated HIV infection.
Samaras K; Gan SK; Peake PW; Carr A; Campbell LV
Obesity (Silver Spring); 2009 Jan; 17(1):53-9. PubMed ID: 19008869
[TBL] [Abstract][Full Text] [Related]
17. The role of multicomponent therapy in the metabolic syndrome, inflammation and cardiovascular risk in obese adolescents.
Masquio DC; de Piano A; Campos RM; Sanches PL; Carnier J; Corgosinho FC; Netto BD; Carvalho-Ferreira JP; Oyama LM; Nascimento CM; de Mello MT; Tufik S; Dâmaso AR
Br J Nutr; 2015 Jun; 113(12):1920-30. PubMed ID: 25907896
[TBL] [Abstract][Full Text] [Related]
18. Elevated interleukin-18 levels are associated with the metabolic syndrome independent of obesity and insulin resistance.
Hung J; McQuillan BM; Chapman CM; Thompson PL; Beilby JP
Arterioscler Thromb Vasc Biol; 2005 Jun; 25(6):1268-73. PubMed ID: 15790931
[TBL] [Abstract][Full Text] [Related]
19. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes.
Esser N; Legrand-Poels S; Piette J; Scheen AJ; Paquot N
Diabetes Res Clin Pract; 2014 Aug; 105(2):141-50. PubMed ID: 24798950
[TBL] [Abstract][Full Text] [Related]
20. Abdominal obesity and cardiovascular disease: is inflammation the missing link?
Després JP
Can J Cardiol; 2012; 28(6):642-52. PubMed ID: 22889821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
